Literature DB >> 16690430

Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance.

Shi-Xiong Liang1, Xiao-Dong Zhu, Zhi-Yong Xu, Ji Zhu, Jian-Dong Zhao, Hai-Jie Lu, Yun-Li Yang, Long Chen, An-Yu Wang, Xiao-Long Fu, Guo-Liang Jiang.   

Abstract

PURPOSE: To identify risk factors relevant to radiation-induced liver disease (RILD) and to determine the hepatic tolerance to radiation. METHODS AND MATERIALS: The data of 109 primary liver carcinomas (PLC) treated with hypofractionated three-dimensional conformal radiation therapy (3D-CRT) were analyzed. Seventeen patients were diagnosed with RILD and 13 of 17 died of it.
RESULTS: The risk factors for RILD were late T stage, large gross tumor volume, presence of portal vein thrombosis, association with Child-Pugh Grade B cirrhosis, and acute hepatic toxicity. Multivariate analyses demonstrated that the severity of hepatic cirrhosis was a unique independent predictor. For Child-Pugh Grade A patients, the hepatic radiation tolerance was as follows: (1) Mean dose to normal liver (MDTNL) of 23 Gy was tolerable. (2) For cumulative dose-volume histogram, the tolerable volume percentages would be less than: V5 of 86%, V10 of 68%, V15 of 59%, V20 of 49%, V25 of 35%, V30 of 28%, V35 of 25%, and V40 of 20%. (3) Tolerable MDTNL could be estimated by MDTNL (Gy) = -1.686 + 0.023 * normal liver volume (cm3).
CONCLUSION: The predominant risk factor for RILD was the severity of hepatic cirrhosis. The hepatic tolerance to radiation could be estimated by dosimetric parameters.

Entities:  

Mesh:

Year:  2006        PMID: 16690430     DOI: 10.1016/j.ijrobp.2005.12.031

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  82 in total

Review 1.  Hepatic radiation toxicity: avoidance and amelioration.

Authors:  Chandan Guha; Brian D Kavanagh
Journal:  Semin Radiat Oncol       Date:  2011-10       Impact factor: 5.934

Review 2.  Radiation-associated liver injury.

Authors:  Charlie C Pan; Brian D Kavanagh; Laura A Dawson; X Allen Li; Shiva K Das; Moyed Miften; Randall K Ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

3.  [Stereotactic body radiotherapy for the treatment of hepatocellular cancer. Pooled analysis of two phase I/II trials].

Authors:  D Habermehl; S E Combs
Journal:  Strahlenther Onkol       Date:  2013-12       Impact factor: 3.621

4.  Differential hepatic avoidance radiation therapy: Proof of concept in hepatocellular carcinoma patients.

Authors:  Stephen R Bowen; Jatinder Saini; Tobias R Chapman; Robert S Miyaoka; Paul E Kinahan; George A Sandison; Tony Wong; Hubert J Vesselle; Matthew J Nyflot; Smith Apisarnthanarax
Journal:  Radiother Oncol       Date:  2015-04-28       Impact factor: 6.280

5.  Validation of the liver mean dose in terms of the biological effective dose for the prevention of radiation-induced liver damage.

Authors:  Hiroshi Doi; Norihisa Masai; Kenji Uemoto; Osamu Suzuki; Hiroya Shiomi; Daisaku Tatsumi; Ryoong-Jin Oh
Journal:  Rep Pract Oncol Radiother       Date:  2017-05-05

6.  Estimating functional liver reserve following hepatic irradiation: adaptive normal tissue response models.

Authors:  Matthew H Stenmark; Yue Cao; Hesheng Wang; Andrew Jackson; Edgar Ben-Josef; Randall K Ten Haken; Theodore S Lawrence; Mary Feng
Journal:  Radiother Oncol       Date:  2014-05-08       Impact factor: 6.280

Review 7.  Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance.

Authors:  Christopher H Crane; Eugene J Koay
Journal:  Cancer       Date:  2016-03-07       Impact factor: 6.860

8.  Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study.

Authors:  Jian-Dong Zhao; Jin Liu; Zhi-Gang Ren; Ke Gu; Zhen-Hua Zhou; Wen-Tao Li; Zhen Chen; Zhi-Yong Xu; Lu-Ming Liu; Guo-Liang Jiang
Journal:  Radiat Oncol       Date:  2010-02-12       Impact factor: 3.481

9.  Comparison of coplanar and noncoplanar intensity-modulated radiation therapy and helical tomotherapy for hepatocellular carcinoma.

Authors:  Chen-Hsi Hsieh; Chia-Yuan Liu; Pei-Wei Shueng; Ngot-Swan Chong; Chih-Jen Chen; Ming-Jen Chen; Ching-Chung Lin; Tsang-En Wang; Shee-Chan Lin; Hung-Chi Tai; Hui-Ju Tien; Kuo-Hsin Chen; Li-Ying Wang; Yen-Ping Hsieh; David Y C Huang; Yu-Jen Chen
Journal:  Radiat Oncol       Date:  2010-05-23       Impact factor: 3.481

10.  Bone marrow-derived stromal cell therapy in cirrhosis: clinical evidence, cellular mechanisms, and implications for the treatment of hepatocellular carcinoma.

Authors:  Jeffrey M Vainshtein; Rafi Kabarriti; Keyur J Mehta; Jayanta Roy-Chowdhury; Chandan Guha
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-15       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.